Literature DB >> 12053708

Theodore E. Woodward Award. How bacterial enterotoxins work: insights from in vivo studies.

J Thomas Lamont1.   

Abstract

Clostridium difficile is a spore forming, gram-positive anaerobic bacillus first described in 1935 by Hall and O'Toole as a commensal organism in the fecal flora of healthy newborn infants (1). The organism was given its unusual name because it grew slowly and was difficult to isolate in pure culture. Its presence in the stool of healthy neonates suggested that C. difficile was a nonpathogen, even though it produced toxins in broth culture. Following its original description, C. difficile passed quickly into relative obscurity in the 1960's and 1970's when antibiotic-associated pseudomembranous colitis became prevalent following the introduction into clinical practice of broad spectrum antibiotics. The frequent association of clindamycin and lincomycin therapy with pseudomembranous colitis led to the term "clindamycin colitis" (2). A breakthrough occurred in 1978 when C. difficile was identified as the source of a cytotoxin in the stool of patients with pseudomembranous colitis (3). During the two decades since its rediscovery, a great deal has been learned about the pathophysiology, epidemiology and management of C. difficile infection, yet many challenges remain. Currently this organism infects over 30% of individuals admitted to United States hospitals, making C. difficile colitis one of the most common nosocomial infections (4). It is estimated that approximately 10-12 million adults are infected with this organism each year in the United States, about a third of whom become symptomatic. The disease burden in the elderly is particularly severe as they are hospitalized more frequently and for longer duration. The pathophysiology of C. difficile diarrhea requires alteration of the colonic microflora by antibiotics, colonization by C. difficile, and release of two potent enterotoxins designated A and B (5). The toxins of Clostridium difficile are required virulence factors in both animals and humans since non-toxigenic strains do not cause disease. Recent cloning and sequencing of the toxin genes reveals extensive amino acid homology between them that is reflected in common molecular and cellular mechanisms. Both toxins damage cells by modifying the rho family of proteins, key regulators of cellular actin. C. difficile infection causes a florid acute inflammatory response seen in patients with pseudomembranous colitis. It is now realized that neurons and immune cells of the lamina propria are major determinants of toxin-induced diarrhea and mucosal damage. Early critical events following toxin exposure are release of the neuropeptides substance P and calcitonin gene related peptide (CGRP) from sensory afferent neurons and activation of lamina propria macrophages and intestinal mast cells. These peptides in turn release a complex cascade of other inflammatory mediators from lamina propria cells (5). The importance of the host immune response, specifically serum IgG directed against toxin A, is now recognized as a critical determinant of disease expression in man.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12053708      PMCID: PMC2194470     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  34 in total

Review 1.  Large clostridial cytotoxins--a family of glycosyltransferases modifying small GTP-binding proteins.

Authors:  C von Eichel-Streiber; P Boquet; M Sauerborn; M Thelestam
Journal:  Trends Microbiol       Date:  1996-10       Impact factor: 17.079

2.  C. difficile toxin A increases intestinal permeability and induces Cl- secretion.

Authors:  R Moore; C Pothoulakis; J T LaMont; S Carlson; J L Madara
Journal:  Am J Physiol       Date:  1990-08

Review 3.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

4.  Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients.

Authors:  J Nord; P Ma; D DiJohn; S Tzipori; C O Tacket
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

5.  Neurokinin-1 (NK-1) receptor is required in Clostridium difficile- induced enteritis.

Authors:  I Castagliuolo; M Riegler; A Pasha; S Nikulasson; B Lu; C Gerard; N P Gerard; C Pothoulakis
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

6.  Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.

Authors:  J G Bartlett; T W Chang; M Gurwith; S L Gorbach; A B Onderdonk
Journal:  N Engl J Med       Date:  1978-03-09       Impact factor: 91.245

7.  Serum antibody response to toxins A and B of Clostridium difficile.

Authors:  R Viscidi; B E Laughon; R Yolken; P Bo-Linn; T Moench; R W Ryder; J G Bartlett
Journal:  J Infect Dis       Date:  1983-07       Impact factor: 5.226

8.  Epidemiology of Clostridium difficile in infants.

Authors:  H E Larson; F E Barclay; P Honour; I D Hill
Journal:  J Infect Dis       Date:  1982-12       Impact factor: 5.226

9.  Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli.

Authors:  C O Tacket; G Losonsky; H Link; Y Hoang; P Guesry; H Hilpert; M M Levine
Journal:  N Engl J Med       Date:  1988-05-12       Impact factor: 91.245

10.  Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding.

Authors:  C P Kelly; C Pothoulakis; J Orellana; J T LaMont
Journal:  Gastroenterology       Date:  1992-01       Impact factor: 22.682

View more
  10 in total

Review 1.  Clostridium difficile in the ICU: the struggle continues.

Authors:  Linda D Bobo; Erik R Dubberke; Marin Kollef
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

Review 2.  Intestinal colonization resistance.

Authors:  Trevor D Lawley; Alan W Walker
Journal:  Immunology       Date:  2013-01       Impact factor: 7.397

3.  Clostridium difficile toxin A decreases acetylation of tubulin, leading to microtubule depolymerization through activation of histone deacetylase 6, and this mediates acute inflammation.

Authors:  Hyo Jung Nam; Jin Ku Kang; Sung-Kuk Kim; Keun Jae Ahn; Heon Seok; Sang Joon Park; Jong Soo Chang; Charalabos Pothoulakis; John Thomas Lamont; Ho Kim
Journal:  J Biol Chem       Date:  2010-08-09       Impact factor: 5.157

4.  Detection of bacterial DNA in painful degenerated spinal discs in patients without signs of clinical infection.

Authors:  Peter Fritzell; Tomas Bergström; Christina Welinder-Olsson
Journal:  Eur Spine J       Date:  2004-05-08       Impact factor: 3.134

5.  Clostridium difficile in paediatric populations.

Authors:  Upton D Allen
Journal:  Paediatr Child Health       Date:  2014-01       Impact factor: 2.253

6.  Clostridioides difficile Infection in Children: A 5-Year Multicenter Retrospective Study.

Authors:  Danilo Buonsenso; Rosalia Graffeo; Davide Pata; Piero Valentini; Carla Palumbo; Luca Masucci; Antonio Ruggiero; Giorgio Attinà; Manuela Onori; Laura Lancella; Barbara Lucignano; Martina Di Giuseppe; Paola Bernaschi; Laura Cursi
Journal:  Front Pediatr       Date:  2022-04-07       Impact factor: 3.418

Review 7.  The role of Clostridium difficile in the paediatric and neonatal gut - a narrative review.

Authors:  E A Lees; F Miyajima; M Pirmohamed; E D Carrol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-23       Impact factor: 3.267

8.  Community acquired Clostridium difficile in an infant without antibiotic exposure.

Authors:  Jaspreet Singh; Rajesh Vyas
Journal:  J Family Med Prim Care       Date:  2020-02-28

9.  Difference in Vitamin D Levels Between Children with Clostridioides difficile Enteritis and Those with Other Acute Infectious Enteritis.

Authors:  Sang Woo Park; Young June Lee; Eell Ryoo
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2021-01-08

Review 10.  Current and future applications of fecal microbiota transplantation for children.

Authors:  Chien-Chang Chen; Cheng-Hsun Chiu
Journal:  Biomed J       Date:  2021-11-12       Impact factor: 7.892

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.